KR930019630A - 셀폰아미도- 및 셀폰아미도카보닐피리딘-2-카복스아미드 및 이의 피리딘-n-옥사이드, 이의 제조방법 및 약제로서 이의용도 - Google Patents

셀폰아미도- 및 셀폰아미도카보닐피리딘-2-카복스아미드 및 이의 피리딘-n-옥사이드, 이의 제조방법 및 약제로서 이의용도 Download PDF

Info

Publication number
KR930019630A
KR930019630A KR1019930004589A KR930004589A KR930019630A KR 930019630 A KR930019630 A KR 930019630A KR 1019930004589 A KR1019930004589 A KR 1019930004589A KR 930004589 A KR930004589 A KR 930004589A KR 930019630 A KR930019630 A KR 930019630A
Authority
KR
South Korea
Prior art keywords
alkyl
alkoxy
alkylamino
radical
carbamoyl
Prior art date
Application number
KR1019930004589A
Other languages
English (en)
Inventor
바이트만 클라우스
빅켈 마르틴
귄쯜러-푸칼 폴크마르
Original Assignee
테르가우, 바이서트
훽스트 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 테르가우, 바이서트, 훽스트 아크티엔게젤샤프트 filed Critical 테르가우, 바이서트
Publication of KR930019630A publication Critical patent/KR930019630A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

본 발명은 하기 일반식(Ⅰ)의 설폰아미도- 및 설폰아미도카보닐피리딘-2카복스아미드 및 특히 섬유성 질환에 대한 이의 약제로서의 용도에 관한 것이다.

Description

설폰아미도- 및 설폰아미도카보닐피리딘-2-카복스아미드 및 이의 피리딘-N-옥사이드, 이의 제조방법 및 약제로서 이의 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (2)

  1. 하기 일반식(I)의 설폰아미도―또는 설폰아미도카보닐 피리딘―2―카복스아미드 또는 이의 피리딘―N―옥사이드.
    상기식에서, A는 R3이고 B는 X―NR6R7이거나, B는R3이고 A는 X―NR6R7이며, X는 단일결합 또는 ―CO―이고,R1, R2및R3은 동일하거나 상이하며 수소, 비치환 또는 치환된(C1-C6)―알킬, (C1-C6) ―알콕시, 할로겐, 특히 불소, 염소 또는 브롬, 니트릴, 하이드록실 또는 아미노이며,R6은 수소, (C1-C6)―알킬 또는 N―보호그룹, 예를 들면,(C1-C8)―알카노일, (C1-C8)―알킬바모일, (C1-C6)―알콕시카보닐, 벤질옥시카보닐, (C1-C10)―아실옥시―(C1-C6)알킬, 바람직하게는 (C1-C10)―알카노일옥시―(C1-C6)―알킬, 벤조일옥시―(C1-C6)―알킬, 벤질옥시카보닐옥시―(C1-C6)―알킬 또는 (C1-C6)―알콕시카보닐옥시―알킬, 또는 (C1-C8)―알킬, (C1-C8)―하이드록시알킬, (C1-C4)―알콕시―(C1-C8)―알킬, 페닐, 벤질, 또는 하이드록실 또는 (C1-C4)―알콕시에 의해 1 내지 3회 치환될 수 있는 (C1-C)알킬에 의해 1 내지 3회 임의로 치환된 1―, 2―, 3―, 4가 생리학적으로 유용한 양이온, 특히 Na, K, Mg, Ca, Al, 또는 암모늄이온, 또는 염기성 아미노산 유도체의 양이온이고,R7은 ―SO2H를 제외한, 하기 일반식(Ⅱ)의 라디칼이며,
    ―Y―〔C―U〕r―D―W (Ⅱ)
    〔상기식에서, Y는 ―SO2― 또는 ―CO―이고, C는 결합, 또는 직쇄 또는 축쇄 지방족(C1-C16) ―알칸디일 또는 지환족(C2-C16) ―알칸디일 라디칼 또는 직쇄 또는 측쇄(C2-C16) ―알칸디일 또는 사이클로알켄디일 라디칼, 또는(C2-C16) ―알칸디일 라디칼 또는(C2-C16) ―알케닌디일 라디칼이며, 이들은 각각 하나 이상의 C―C다중 결합을 함유할 수 있고, U는 결합 또는 수소, 또는 다음 일련의 헤테로원자 그룹 ―CO―, ―O(CO)―, ―(CO)―O―, ―(CO)NR―, NR(CO)―, ―O―, ―SO―, ―SO2―, ―NR(여기에서, R은 (C1-C3)―알킬 또는 수소이다)중의 라디칼이며, r은 1, 2, 3 또는 4이고, C는 결합 또는 수소, 또는 직쇄 또는 측쇄 지방족 (C1-C10)―알켄디일 라디칼, (C2-C10)―알킨디일 라디칼 또는 (C2-C10)―알케닌디일 라디칼이며, 이들은 각각 하나 이상의 C―C다중 결합을 함유할 수 있고, W는 결합 또는 수소, 또는 (C8-C10) ―지환족 알킬, 알케닐, 알키닐 또는 알케니닐 라디칼 또는 (C6-C10)―아릴 라디칼 또는 5― 또는 6원 헤테로아릴 라디칼이며, 여기에서 가변성분 C 또는 D 또는 W중 하나 이상은 결합이 아니고, C가 결합이 아니거나 D 및/또는 W가 결합이 아닐 경우, U는 헤테로원자 그룹일 뿐이고; C및/또는 W는, 결합 또는 수소가 아닐 경우, 바람직하게는 이들의 부분에서 치환된다.〕 R4및R5는 서로 독립적으로 수소 또는 A) 비치환 또는 치환된 (C1-C12)―알콕시 라디칼, (C3-C8)―사이클로알콕시 라디칼, (C6-C12)―아릴옥시 라디칼 또는 (C7-C11)―아르알킬옥시 라디칼이며, 이들은 할로겐, 트리플루오로메틸,(C1-C6) ―알콕시, 하이드록실, (C1-C6)―하이드록시알킬, NR′R″ 또는 시아노에 의해 일― 또는 다치환, 바람직하게는 일― 또는 이치환되고, B) 비치환 또는 치환된, 직쇄 또는 측쇄의 지방족 또는 지환족 (C1-C12)―알킬 라디칼, (C1-C12)―알케닐 라디칼 또는 (C1-C12)―알키닐 라디칼이거나 또는 C) 비치환 또는 치환된 (C1-C12)―아릴 라디칼, (C7-C11)―아르알킬 라디칼 또는 헤트아릴 라디칼이며, R′ 및 R″는 동일하거나 상이하며 수소, (C6-C12)―아릴, (C1-C8)―알킬, (C1-C8)―알킬카보닐, (C7-C11)―아르알킬 카보닐 또는 (C6-C12)―아릴카보닐이거나, 질소원자와 함께 포화된 헤테로사이클릭 환, 바람직하게는 5― 또는 6원환을 형성하며, n은 0 또는 1이다.
  2. 제1항에 있어서, A는 R3이고 B는 X―NR6R7이거나, B는 R3이고 A는 X―NR6R7이며, X는 단일결합 또는 ―CO―이고, R1, R2및R3은 동일하거나 상이하며 수소, 비치환 또는 치환된 (C1-C6)―알킬, (C1-C6)―알콕시, 할로겐, 특히 불소, 염소 또는 브롬, 니티릴, 하이드록실 또는 아미노이며, R6은 수소, (C1-C6)―알킬 또는 N―보호 그룹, 예를 들면, (C1-C8)―알카노일, (C1-C6)―알킬바모일, (C1-C6)―알콕시카보닐, 벤질옥시카보닐, (C1-C10)―아실옥시―(C1-C6)―알킬, 바람직하게는 (C1-C10)―알카노일옥시―(C1-C6)―알킬, 벤조일옥시―(C1-C6)―알킬, 벤질옥시카보닐옥시―(C1-C6)―알킬 또는 (C1-C6)―알콕시카보닐옥시―알킬, (C1-C8)―알킬, (C1-C8) ―하이드록시알킬, (C1-C4)―알콕시―(C1-C8) ―알킬, 페닐, 벤질, 또는 하이드록실 또는 ―(C1-C4)-알콕시에 의해 1 내지 3회 치환될 수 있는 (C1-C8)-알킬에 의해 1 내지 3회 임의로 치환된 1-, 2-, 3-, 4가 생리학적으로 유용한 양이온, 특히 　Na, K, Mg2 ,Ca2 , Al3 , 또는 암모늄 이온, 또는 염기성 아미노산 유도체의 양이온이며, R7은 -SO2H를 제외한, 하기 일반식 [Ⅱ]의 라디칼이며,
    ―Y―〔C―U〕r―D―W (Ⅱ)
    [상기식에서, Y는 ―SO2― 또는 ―CO―이고, C는 결합, 또는 직쇄 또는 축쇄 지방족(C1-C16) ―알칸디일 또는 지환족(C3-C10) ―알칸디일 라디칼 또는 직쇄 또는 측쇄(C2-C16) ―알칸디일 또는 사이클로알켄디일 라디칼, 또는(C2-C16) ―알칸디일 라디칼 또는(C2-C16) ―알케닌디일 라디칼이며, 이들은 각각 하나 이상의 C―C다중 결합을 함유할 수 있고, U는 결합 또는 수소, 또는 다음 일련의 헤테로원자 그룹 ―CO―, ―O(CO)―, ―(CO)―O―, ―(CO)NR―, NR(CO)―, ―O―, ―SO―, ―SO2―, ―NR(여기에서, R은 (C1-C3)―알킬, (C1-C8)-알카노일, ((C7-C16)-아르알카노일, (C6-C12)-아로일 또는 수소이다)중의 라디칼이며, r은 1, 2, 3 또는 4이고, C는 결합 또는 수소, 또는 직쇄 또는 측쇄 지방족 (C1-C10)―알켄디일 라디칼, (C2-C10)―알킨디일 라디칼 또는 (C2-C10)―알케닌디일 라디칼이며, 이들은 각각 하나 이상의 C―C다중 결합을 함유할 수 있고, W는 결합 또는 수소, 또는 (C3-C10) ―지환족 알킬, 알케닐, 알키닐 또는 알케니닐 라디칼 또는 (C8-C10)―아릴 라디칼 또는 5― 또는 6원 헤테로아릴 라디칼이며, 여기에서 가변성분 C 또는 D 또는 W중 하나 이상은 결합이 아니고, C가 결합이 아니거나 D 및/또는 W가 결합이 아닐 경우, U는 헤테로원자 그룹일 뿐이고 ; C 및/또는 W는 , 결합 또는 수소가 아닐경우, 다음을 포함하는 시리즈중의 동일하거나 상이한 5개 이하의 치환체의 조합에 의해 이들이 바람직하게 치환되며 ; 하이드록실, 할로겐, 시아노, 트리플루오로메틸, 니트로, 카복실, (C1-C12) ―알킬, (C3-C8)―사이클로알킬, (C8-C12)―아릴, (C7-C16) ―아르알킬, (C3-C12) ―알케닐, (C3-C12) ―알키닐, (C1-C12)―알콕시, (C1-C12)―알콕시― (C1-C12)―알킬, (C1-C12)―알콕시― (C1-C12) ―알콕시, (C6-C12) ―아릴옥시, (C7-C16)―아르알킬옥시, (C1-C8)―하이드록실알킬, ―O-〔CH2〕CfH(2f+1-g)Fg, -OCF2Cl, -OCF2-CHFCl, (C1-C12)―알킬카보닐, (C3-C8)―사이클로알킬카보닐, (C8-C12)―아릴카보닐, (C7-C16)―아르알킬카보닐, 신나모일, (C3-C12)―알케닐카보닐, (C3-C12)―알키닐카보닐, (C1-C12)―알콕시카보닐, (C1-C12)―알콕시― (C1-C12)―알콕시카보닐, (C6-C12)―아릴옥시카보닐, (C7-C16)―아르알콕시 카보닐, (C3-C8)―사이클로알콕시카보닐, (C8-C12)―알케닐옥시카보닐, (C3-C12)―알키닐옥카보닐, (C3-C8)―알키닐옥시카보닐, (C1-C12)―알킬카보닐옥시, (C3-C8)―사이클로알킬카보닐옥시, (C8-C12)―아릴카보닐옥시, (C6-C12)―아르알킬카보닐옥시, 신나모일옥시 (C3-C12)―알케닐카보닐옥시, (C8-C12)―알키닐카보닐옥시, (C1-C12)―알콕시카보닐옥시, (C1-C12)―알콕시― (C6-C12)―알콕시카보닐옥시, (C7-C18)―아릴옥시카보닐옥시, (C3-C8)―아르알킬옥시카보닐옥시, (C3-C8)―사이클로알콕시카보닐옥시, (C3-C12)―알케닐옥시카보닐옥시, (C3-C12)―알키닐옥시카보닐옥시, 카바모일, N―(C1-C12) ―알킬카바모일, N,N―디―(C1-C12) ―알킬카바모일, N―(C3-C8)―사이클로알킬카바모일, N―(C6-C16) ―아릴카바모일, N―(C7-C16)―아르알킬카바모일, N―(C1-C10) ―알킬―N―(C6-C16)아릴카바모일, N―(C1-C10)―알킬―N―(C7-C16)―아르알킬카바모일, N―((C1-C10)―알콕시―(C1-C10)알킬)카바모일, N―(C6-C16) ―아릴옥시―(C1-C10)―알킬)카바모일, N―((C7-C16)―아르알킬옥시―(C1-C10)―알킬)카바모일, N―알킬―N(―아릴옥시―(C1-C10) ―알킬)카바모일, N―(C1-C10)―알킬―N―((C7-C16)―아르알킬옥시―(C1-C10)―알킬)카바모일, 카바모일옥시, N―(C1-C12)―알킬카바모일옥시,N,N―디―(C1-C12)―알킬카바모일옥시, N―(C3-C8)―사이클로알킬카바모일옥시, N―(C6-C16)―아릴카바모일옥시, N―(C7-C16)―아르알킬카바모일옥시, N―(C1-C10)―알킬―N―(C6-C12)―아릴 카바모일옥시, N―(C1-C10)―알킬―N―(C7-C16)―아르알킬카바모일옥시, N―((C1-C10)―알콕시―(C1-C10)―알킬)카바모일옥시, N―((C6-C16)―아릴옥시―(C1-C10) ―알킬)카바모일옥시, N―((C7-C16)―아르알킬옥시―(C1-C10)―알킬)카바모일옥시, N―(C1-C10) ―알킬―N―((C1-C10)―알콕시―(C1-C10)―알킬)카바모일옥시,N―(C1-C10)-알킬―N―((C6-C16)―아릴옥시―((C1-C10) ―알킬) 카바모일옥시, N―(C1-C10)―알킬―N―((C7-C16)―아르알킬옥시―(C1-C10) ―알킬)카바모일옥시, 아미노, (C1-C12)―알킬아미노, 디―(C1-C12) ―알킬아미노, (C3-C8)―사이클로알킬아미노, (C3-C12)―알케닐아미노, (C3-C12)―알키닐아미노, N―(C6-C12) ―아릴아미노, N―(C7-C11) ―아르알킬아미노, N―(C1-C10)―알킬―(C7-C10)―아르알킬아미노, N―(C1-C10)―알킬―N―(C6-C12)―알킬아미노, (C1-C12)―알콕시아미노, (C1-C12)―알콕시―N―(C1-C10)―알킬아미노, (C1-C12)―알카노일아미노, (C3-C8)―사이클로알카노일아미노, (C6-C12)―아로일아미노, (C7-C16) ―아르알카노일아미노, (C1-C12)―알카노일―N―(C1-C10)―알킬아미노, (C3-C8) ―사이클로알칸노일―N―(C1-C10)-알킬아미노, (C6-C12)―아로일―N―(C1-C10) ―알킬아미노, (C7-C11)―아르알카노일―N―(C1-C10)―알킬아미노, (C1-C12)―알카노일아미노―(C1-C8)―알킬, (C3-C8)―사이클로알카노일아미노―(C1-C8) ―알킬, (C6-C16)―아로일아미노―(C1-C8)―알킬,(C7-C16)―아르알카노일아미노―(C1-C8)―알킬, 아미노―(C1-C10) ―알킬, N―(C1-C10)―알킬아미노―(C1-C10)―알킬, N,N―디―(C1-C10)―알킬아미노―(C1-C10) ―알킬아미노―(C1-C10)―알킬, (C3-C8)―사이클로알킬아미노―(C1-C10)―알킬, (C1-C12)―알킬머캅토, (C1-C12)―알킬설피닐, (C1-C12)―알킬설포닐, (C6-C16)―아릴머캅토, (C6-C16)―아릴설피닐, (C6-C16)―아릴설포닐, (C7-C16)―아르알필머캅토, (C7-C16)―아르알킬설피닐, (C7-C16)―아르알킬설포닐, 설파모일, N―(C1-C10)―알킬설파모일, N,N―디―(C1-C10)―알킬설파모일, (C3-C8)―사이클로알킬설파모일, N―(C6-C16)―아릴설파모일, N―(C7-C16)―아르알킬설파모일, ―(C1-C10)―아킬―N―(C6-C16)―아릴설파모일, N―(C1-C10) ―알킬―N―(C7-C16)아르알킬설파모일, (C1-C10)―알킬설폰아미도, N―((C1-C10)―알킬―(C1-C10)알킬설폰아미도, (C7-C16)알킬설폰아미도, N―((C1-C10알킬-((C7-C16)아르알킬설폰아미도, 여기에서, 아릴 라디칼을 함유하는 라디칼은 이의 아릴 부위상에서 다음을 포함하는 시리즈중의 동일하거나 상이한 치환체 1 내지 5개에 의해 일부가 치환될 수 있으며 : 하이드록실, 할로겐, 시아노, 트리플루오로메틸, 니트로, 카복실, (C1-C12)―알킬, (C3-C8)―사이클로알킬, (C6-C12)―아릴, (C7-C16)―아르알킬, (C3-C12)―알케닐, (C3-C12)―알키닐, (C1-C12)―알콕시, (C1-C12)―알콕시―(C1-C12)―알킬, (C1-C12)―알콕시― (C1-C12) ―알콕시, (C6-C12)―아릴옥시, (C7-C16)―아르알킬옥시, (C1-C8)―하이드록시알킬, ―O―[CH2]xCfH(2f+1=g)-OCF2Cl, -OCF2-CHFCl, (C1-C12)―알킬카보닐, (C3-C8)―사이클로알킬카보닐, (C6-C12)―아릴카보닐, (C7-C16)―아르알킬카보닐, 신나모일, (C3-C12)―알케닐카보닐, (C3-C12)―알키닐카보닐, (C1-C12)―알콕시카보닐, (C1-C12)―알콕시―(C1-C12)―알콕시카보닐, (C1-C12)―알콕시카보닐, (C1-C12)―알콕시―(C1-C12)―알콕시카보닐, (C6-C10)―아릴옥시카보닐, (C7-C16)―아르알콕시카보닐; (C3-C8)―사이클로알콕시카보닐, (C3-C12)―알케닐옥시카보닐, (C3-C12)―사이클로알콕시카보닐, (C1-C12)―알킬카보닐옥시, (C3-C8)―사이클로알킬카보닐옥시, (C6-C12)―아릴카보닐옥시, (C7-C16)―아르알킬카보닐옥시, 신나모일옥시, (C3-C12)―알키닐카보닐옥시, (C1-C12)―알콕시카보닐옥시, (C1-C12)―알콕시―(C1-C12)―알콕시카보닐옥시, (C6-C12)―아릴옥시카보닐옥시, (C7-C16)―아르알킬옥시카보닐옥시, (C3-C8)―사이클로알콕시카보닐옥시, (C3-C12)―알케닐옥시카보닐옥시, (C3-C12)―알키닐옥시카보닐옥시, 카바모일, N―(C1-C12)―알킬카바모일, N,N―디―(C1-C12)―알킬카바모일, N―(C3-C8)―사이클로알킬카바모일, N―(C6-C16)아릴카바모일, N―(C7-C16)아르알킬카바모일, N―(C1-C10)―알킬―N―(C6-C16)―아릴카바모일, N―(C1-C10)―알킬―N―(C7-C16)―아르알킬카바모일, N―((C1-C10)―알콕시―(C1-C10)―알킬)카바모일,N-((C6-C16)-아릴옥시-(C1-C10))-알킬)카바모일), N-((C7-C16)-아르알킬옥시-(C1-C10)-알킬)카바모일, N-((C1-C12)-알킬-N((C1-C10)-아릴옥시-(C1-C10)-알킬)카바모일, N-((C1-C10)-알킬-N(-아릴옥시-(C1-C10)-알킬)카바모일, N-((C6-C16)-아릴옥시-(C1-C10)-알킬)카바모일, N―(C1-C10-)알킬)카바모일,N-((C7-C16)-아르알킬옥시-(C1-C10)-알킬)카바모일,카바모일옥시,N-(C1-C12)―알킬카바모일옥시,N,N-디-(C1-C12)-알킬카바모일옥시, N-(C3-C8)-사이클로알킬카바모일옥시, N-(C6-C16)-아릴카바모일옥시, N-(C7-C16)- 아르알킬카바모일옥시, N―(C1-C10)―알킬-N-(C6-C12)-아릴카바모일옥시, N―(C1-C10)―알킬-N-(C6-C12)-아르알킬카바모일옥시, N―(C1-C10)―알콕시-(C1-C10)-알킬)카바모일옥시, N―(C6-C16)-아릴옥시-(C1-C10)-알킬)카바모일옥시, N-((C7-C16)-아르알킬옥시-(C1-C10)-알킬)카바모일옥시, N―(C1-C10)-알킬-N-((C1-C10)-알콕시-(C1-C10)-알킬)카바모일옥시, N―(C1-C10)-알킬-N-((C6-C16)-아릴옥시-(C1-C10)-알킬)카바모일옥시, N―(C1-C10)-알킬-N-((C7-C16)-아르알킬옥시-(C1-C10)-알킬)카바모일옥시, 아미노, (C1-C12)-알킬아미노, 디-(C1-C12)-알킬아미노, (C3-C8)-사이클로알킬아미노, (C3-C12)-알케닐아미노, (C3-C12)-알키닐아미노, N-(C6-C12)-아릴아미노, N-(C7-C11)-아르알킬아미노, N―(C1-C10)-알킬-(C7-C16)-아르알킬아미노, N―(C1-C10)-알킬-(C6-C12)-알킬아미노, (C1-C12)-알콕시아미노, (C1-C12)-알콕시-N-(C1-C10)-알킬아미노, (C1-C12)-알카노일아미노, (C3-C8)-사이클로알킬아미노, (C6-C12)-아로일아미노, (C7-C16)-아르알카노일아미노, (C1-C12)-알카노일-N-(C1-C10)-알킬아미노, (C3-C8)-사이클로알킬아미노-N-(C1-C10)-알킬아미노, (C6-C12)-아로일-N-(C1-C10)-알킬아미노, (C7-C11)-아르알카노일-N-(C1-C10)-알킬아미노, (C1-C12)-알카노일아미노-(C1-C8)-알킬, (C3-C8)-사이클로알킬아미노-(C1-C8)-알킬, (C6-C16)-아로일아미노-(C1-C8)-알킬, (C7-C16)-아르알카노일아미노-(C1-C8)-알킬, 아미노-(C1-C10)-알킬, N-(C1-C10)-알킬아미노-(C1-C10)-알킬, N,N-디-(C1-C10)-알킬아미노-(C1-C10)-알킬아미노-(C1-C10)-알킬, (C3-C8)-사이클로알킬아미노-(C1-C10)-알킬, (C1-C12)-알킬커갑토, (C1-C12)-알킬설피닐, (C1-C12)-알킬설포닐, (C1-C16)-아릴머갑토, (C6-C16)-아릴설피닐, (C6-C16)-아릴설포닐, (C7-C16)-아르알킬머갑토, (C7-C16)-아르알킬설피닐, (C7-C16)-아르알킬설포닐, 설포마일, N-(C1-C10)-알킬설파모일, N,N-디-(C1-C10)-알킬설파모일, (C3-C8)-사이클로알킬설파모일, N-(C6-C16)-아릴설파모일, N-(C7-C16)-아르알킬설파모일, N-(C1-C10)-아킬-N-(C6-C16)-아릴설파모일,
    N-(C1-C10)-알킬-N-(C7-C16)아르알킬설파모일, (C1-C10)-알킬설폰아미도, N-((C1-C10)-알킬)-(C1-C10)-알킬설폰아미도, (C7-C16)-아르알킬설폰아미도, N-((C1-C10)-알킬)-(N-((C1-C10)-알킬)-아르알킬설폰아미도, 여기에서, 아릴 라디칼을 함유하는 라디칼은 이의 아릴 부위상에서 다음을 포함하는 시리즈중의 동일하거나 상이한 치환체 1 내지 5개에 의해 일부가 치환될 수 있으며 : 하이드록실, 할로겐, 시아노, 트리플루오로메틸, 니트로, 카복실, (C1-C12)-알킬, (C3-C8)―사이클로알킬, (C6-C12)-아릴, (C7-C16)-아르알킬, (C3-C12)-알케닐, (C3-C12)-알키닐, (C1-C12)-알콕시, (C1-C12)-알콕시-(C1-C12)-알킬, (C1-C12)-알콕시-(C1-C12)-알콕시, (C6-C12)-아릴옥시, (C7-C16)-아르알킬옥시, (C1-C8)-하이드록시알킬, -O-〔CH2〕CfH(2f+1-g)Fg-OCF2Cl,-OCF2-CHFCl, (C1-C12)―알킬카보닐, (C3-C8)-사이클로알킬카보닐, (C6-C12)-아릴카보닐, (C7-C16)-아르알킬카보닐, 신나모일, (C3-C12)-알키닐카보닐, (C3-C12)-알콕시카보닐, (C1-C12)-알콕시-(C1-C12)-알콕시카보닐, (C1-C12)-알콕시카보닐, (C1-C12)-알콕시-(C1-C12)-알콕시카보닐, (C6-C10)-아릴옥시카보닐, (C7-C16)-아르알콕시카보닐, (C3-C8)-사이클로알코시카보닐, (C3-C12)-알케닐오시카보닐, (C3-C12)-사이클로알콕시카보닐, (C1-C12)-알킬카보닐옥시, (C3-C8)-사이클로알킬카보닐옥시, (C6-C12)-아릴카보닐옥시, (C7-C16)-아르알킬카보닐 옥시, 신나모일옥시, (C3-C12)-알키닐카보닐옥시, (C1-C12)-알콕시카보닐옥시, (C1-C12)-알콕시-(C1-C12)-알콕시카보닐옥시, (C6-C12)-아릴옥시카보닐옥시, (C7-C16)-아르알킬옥시카보닐옥시, (C3-C8)-사이클로알콕시카보닐옥시, (C3-C12)-알케닐옥시카보닐옥시, (C3-C12)-알키닐옥시카보닐옥시, 카바모일, N-(C1-C12)-알킬카바모일, N.N-디-(C1-C12)-알킬카바모일, N-(C3-C8)-사이클로알킬카바모일, N-(C6-C16)-아릴카바모일, N-(C7-C16)-아르알킬카바모일, N―(C1-C10)―알킬-N-(C6-C16)-아릴카바모일, N―(C1-C10)―알킬-N-(C7-C16)-아르알킬카바모일, N-((C1-C10)-알콕시-(C1-C10)-알킬)카바모일, N―((C6-C16)-아릴옥시-(C1-C10)-알킬)카바모일, N-((C7-C16)-아르알킬옥시-(C1-C10)-알킬)카바모일, 카바모일옥시, N―(C1-C12)―알킬카바모일옥시,N,N-디-(C1-C12)-알킬카바모일옥시, N-(C3-C8)-사이클로알킬카바모일옥시, N-(C6-C16)-아릴카바모일옥시, N-(C1-C10)-알킬-N(C6-C12)-알칼카바모일옥시 N―(C1-C10)―알킬-N-(C6-C12)-아릴카바모일옥시, N―(C1-C10)―알킬-N-(C7-C16)-아르알킬카바모일옥시,N-((C1-C10)-알콕시-(C1-C10)-알킬)카바모일옥시, N―(C6-C16)-아릴옥시-(C1-C10)-알킬)카바모일옥시, (C7-C16)-아르알킬옥시-(C1-C10)-알킬)카바모일옥시, N―(C1-C10)-알킬-N-((C1-C10)-알콕시-(C1-C10)-알킬)카바모일옥시, N―(C1-C10)-알킬-N-((C6-C16)-아릴옥시-(C1-C10)-알킬)카바모일옥시, N―(C1-C10)-알킬-N-((C7-C16)-아르알킬옥시-(C1-C10)-알킬)카바모일옥시, 아미노, (C1-C12)-알킬아미노, 디-(C1-C12)-알킬아미노, (C3-C8)-사이클로알킬아미노, (C3-C12)-알케닐아미노, (C3-C12)-알키닐아미노, N-(C6-C12)-아릴아미노, N-(C7-C11)-아르알킬아미노, N―(C1-C10)-알킬-(C7-C16)-아르알킬아미노, N―(C1-C10)-알킬-N-(C6-C12)-아릴아미노, (C1-C12)-알콕시아미노, (C1-C12)-알콕시-N-(C1-C10)-알킬아미노, (C1-C12)-알카노일아미노, (C3-C8)-사이클로알카노일아미노, (C6-C12)-아로일아미노, (C7-C18)-아르알카노일아미노, (C1-C12)-알카노일-N-(C1-C10)-알킬아미노, (C3-C8)-사이클로카노일-N-(C1-C10)-알킬아미노, (C6-C12)-아로일-N-(C1-C10)-알킬아미노, (C7-C11)-아르알카노일-N-(C1-C10)-알킬아미노, (C1-C12)-알카노일아미노-(C1-C8)-알킬, (C3-C8)-사이클로알킬카노일아미노-(C1-C8)-알킬, (C6-C16)-아로일아미노-(C1-C8)-알킬, (C7-C16)-아르알카노일아미노-(C1-C8)-알킬, 아미노-(C1-C10)-알킬, N-(C1-C10)-알킬아미노-(C1-C10)-알킬, N,N-디-(C1-C10)-알킬아미노-(C1-C10)-알킬아미노-(C1-C10)-알킬, (C3-C8)-사이클로알킬아미노-(C1-C10)-알킬, (C1-C12)-알킬머갑토, (C1-C12)-알킬설피닐, (C1-C12)-알킬설포닐, (C1-C16)-아릴머갑토, (C6-C16)-아릴설포닐, (C7-C16)-아르알킬머갑토, (C7-C16)-아르알킬설피닐, (C7-C16)-아르알킬설포닐, 설파모일, N-(C1-C10)-알킬설파모일, N,N-디-(C1-C10)-알킬설파모일, (C3-C8)-사이클로알킬설파모일, N-(C6-C16)-아릴설파모일, N-(C7-C16)-아르알킬설파모일, N-(C1-C10)-알킬-N-(C6-C16)-아릴설파모일,
    N-(C1-C10)-알킬-N-(C7-C16)-아르알킬설파모일, (C1-C10)-알킬설폰아미도, N-((C1-C10)-알킬)-(C1-C10)-알킬설폰아미도, (C7-C16C7-C16)-아르알킬설폰아미도, R4및 R5는 서로 독립적으로 수소 또는 A) 비치환 또는 치환된 (C1-C12)-알콕시 라디칼, (C3-C8)-사이클로알콕시 라디칼, (C6-C12)-아릴옥시 라디칼 또는( C7-C11)-아르알킬옥시 라디칼이며, 이들은 할로겐, 트리플루오로메틸,
KR1019930004589A 1992-03-24 1993-03-24 셀폰아미도- 및 셀폰아미도카보닐피리딘-2-카복스아미드 및 이의 피리딘-n-옥사이드, 이의 제조방법 및 약제로서 이의용도 KR930019630A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE4209424 1992-03-24
DE?P4209424.0? 1992-03-24
DE?P4238506.7? 1992-11-14
DE4238506 1992-11-14

Publications (1)

Publication Number Publication Date
KR930019630A true KR930019630A (ko) 1993-10-18

Family

ID=25913130

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930004589A KR930019630A (ko) 1992-03-24 1993-03-24 셀폰아미도- 및 셀폰아미도카보닐피리딘-2-카복스아미드 및 이의 피리딘-n-옥사이드, 이의 제조방법 및 약제로서 이의용도

Country Status (24)

Country Link
US (1) US5607954A (ko)
EP (1) EP0562512B1 (ko)
JP (1) JPH0649030A (ko)
KR (1) KR930019630A (ko)
CN (1) CN1076691A (ko)
AT (1) ATE199250T1 (ko)
AU (1) AU657608B2 (ko)
CA (1) CA2092276A1 (ko)
CZ (1) CZ46393A3 (ko)
DE (1) DE59310146D1 (ko)
DK (1) DK0562512T3 (ko)
ES (1) ES2154266T3 (ko)
FI (1) FI102895B1 (ko)
GR (1) GR3035479T3 (ko)
HK (1) HK1011987A1 (ko)
HU (2) HU219224B (ko)
MY (1) MY109143A (ko)
NO (1) NO179867C (ko)
NZ (1) NZ247201A (ko)
PL (1) PL173677B1 (ko)
PT (1) PT562512E (ko)
RU (1) RU2129545C1 (ko)
SK (1) SK280884B6 (ko)
TW (1) TW352384B (ko)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0650960B1 (de) * 1993-11-02 1997-03-05 Hoechst Aktiengesellschaft Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
ATE149486T1 (de) * 1993-11-02 1997-03-15 Hoechst Ag Substituierte heterocyclische carbonsäureamide, ihre herstellung und ihre verwendung als arzneimittel
NZ270267A (en) * 1993-12-30 1997-03-24 Hoechst Ag 3-hydroxypyridin-2yl (and -quinolin-2-yl) carboxamide derivatives and pharmaceutical compositions
DE4410480A1 (de) * 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410423A1 (de) * 1994-03-25 1995-09-28 Hoechst Ag Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE4410454A1 (de) * 1994-03-25 1995-09-28 Hoechst Ag Substituierte heterocyclische Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
DE4410453A1 (de) * 1994-03-25 1995-09-28 Hoechst Ag Substituierte heterocyclische Carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
IL135495A (en) * 1995-09-28 2002-12-01 Hoechst Ag Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
DE19742951A1 (de) 1997-09-29 1999-04-15 Hoechst Schering Agrevo Gmbh Acylsulfamoylbenzoesäureamide, diese enthaltende nutzpflanzenschützende Mittel und Verfahren zu ihrer Herstellung
DE19746287A1 (de) * 1997-10-20 1999-04-22 Hoechst Marion Roussel De Gmbh Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
AR015733A1 (es) * 1998-03-25 2001-05-16 Otsuka Pharma Co Ltd DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO.
US6583318B2 (en) 2001-05-17 2003-06-24 Advanced Syntech, Llc Method for synthesis of α-sulfonamido amide, carboxylic acid and hydroxamic acid derivatives
EP2295060B1 (en) 2001-12-06 2018-10-31 Fibrogen, Inc. Treatment or prevention of ischemic or hypoxic conditions
ES2414706T3 (es) 2001-12-06 2013-07-22 Fibrogen, Inc. Métodos para aumentar la eritropoyetina endógena
US8124582B2 (en) 2002-12-06 2012-02-28 Fibrogen, Inc. Treatment of diabetes
US7618940B2 (en) 2002-12-06 2009-11-17 Fibrogen, Inc. Fat regulation
US8614204B2 (en) * 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
WO2006138511A2 (en) 2005-06-15 2006-12-28 Fibrogen, Inc. Use of hif 1alfa modulators for treatment of cancer
KR100934674B1 (ko) * 2006-03-30 2009-12-31 엘지전자 주식회사 비디오 신호를 디코딩/인코딩하기 위한 방법 및 장치
EP3026044B8 (en) 2006-06-26 2018-12-19 Akebia Therapeutics, Inc. Prolyl hydroxylase inhibitors and methods of use
WO2008147797A2 (en) * 2007-05-25 2008-12-04 Vertex Pharmaceuticals Incorporated Ion channel modulators and methods of use
WO2009002533A1 (en) * 2007-06-27 2008-12-31 The Brigham And Women's Hospital, Inc. Inflammatory bowel disease therapies
NO2686520T3 (ko) 2011-06-06 2018-03-17
RU2627701C2 (ru) 2012-02-22 2017-08-10 Сэнфорд-Бёрнхэм Медикал Рисёрч Инститьют Сульфонамидные соединения и их применение в качестве ингибиторов tnap
TW201512171A (zh) 2013-04-19 2015-04-01 Pfizer Ltd 化學化合物
CN114404414A (zh) 2013-06-13 2022-04-29 阿克比治疗有限公司 用于治疗贫血症的组合物和方法
TWI665190B (zh) 2013-11-15 2019-07-11 阿克比治療有限公司 ｛［５－（３－氯苯基）－３－羥基吡啶－２－羰基］胺基｝乙酸之固體型式，其組合物及用途
US10150734B2 (en) 2015-01-23 2018-12-11 Akebia Therapeutics, Inc. Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
CN106146395B (zh) * 2015-03-27 2019-01-01 沈阳三生制药有限责任公司 3-羟基吡啶化合物、其制备方法及其制药用途
BR112017021097B1 (pt) 2015-04-01 2024-01-02 Akebia Therapeutics, Inc Formulação de dosagem oral e seu uso
TW202406895A (zh) 2018-05-09 2024-02-16 美商阿克比治療有限公司 用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
CN111972405A (zh) * 2020-07-27 2020-11-24 南京太化化工有限公司 一种悬浮剂用助剂及异恶唑草酮悬浮剂

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3432094A1 (de) * 1984-08-31 1986-03-06 Hoechst Ag, 6230 Frankfurt Ester der pyridin-2,4- und -2,5- dicarbonsaeure als arzneimittel zur inhibierung der prolin- und lysinhydroxylase
DE3703959A1 (de) * 1987-02-10 1988-08-18 Hoechst Ag Pyridin-2,4- und 2,5-dicarbonsaeureamide, verfahren zu ihrer herstellung, verwendung derselben sowie arzneimittel auf basis dieser verbindungen
US5153208A (en) * 1987-02-10 1992-10-06 Hoechst Aktiengesellschaft Pyridine-2,4- and -2,5-dicarboxylic acid amides and their medicinal compositions and methods of use
DE3703962A1 (de) * 1987-02-10 1988-08-18 Hoechst Ag Pyridin-2,4- und 2,5-dicarbonsaeure-derivate, verfahren zu ihrer herstellung, verwendung derselben sowie arzneimittel auf basis dieser verbindungen
DE3928144A1 (de) * 1989-08-25 1991-02-28 Hoechst Ag Zyklische pyridin-2,4- und -2,5-dicarbonsaeurediamide, verfahren zu deren herstellung sowie deren verwendung
DE4020570A1 (de) * 1990-06-28 1992-01-02 Hoechst Ag 2,4- und 2,5-substituierte pyridin-n-oxide, verfahren zu deren herstellung sowie deren verwendung

Also Published As

Publication number Publication date
FI102895B (fi) 1999-03-15
RU2129545C1 (ru) 1999-04-27
PL173677B1 (pl) 1998-04-30
SK280884B6 (sk) 2000-09-12
GR3035479T3 (en) 2001-05-31
PT562512E (pt) 2001-06-29
HUT69685A (en) 1995-09-28
ES2154266T3 (es) 2001-04-01
NO179867B (no) 1996-09-23
DK0562512T3 (da) 2001-03-19
MY109143A (en) 1996-12-31
EP0562512A1 (de) 1993-09-29
PL298195A1 (en) 1994-01-10
JPH0649030A (ja) 1994-02-22
NO931056D0 (no) 1993-03-23
EP0562512B1 (de) 2001-02-21
FI931250A (fi) 1993-09-25
US5607954A (en) 1997-03-04
NO179867C (no) 1997-01-02
AU657608B2 (en) 1995-03-16
NO931056L (no) 1993-09-27
NZ247201A (en) 1996-05-28
HK1011987A1 (en) 1999-07-23
CN1076691A (zh) 1993-09-29
HU210714A9 (en) 1995-06-28
HU9300850D0 (en) 1993-06-28
SK22393A3 (en) 1993-10-06
TW352384B (en) 1999-02-11
CA2092276A1 (en) 1993-09-25
CZ46393A3 (en) 1994-01-19
HU219224B (en) 2001-03-28
FI102895B1 (fi) 1999-03-15
ATE199250T1 (de) 2001-03-15
DE59310146D1 (de) 2001-03-29
AU3536993A (en) 1993-09-30
FI931250A0 (fi) 1993-03-22

Similar Documents

Publication Publication Date Title
KR930019630A (ko) 셀폰아미도- 및 셀폰아미도카보닐피리딘-2-카복스아미드 및 이의 피리딘-n-옥사이드, 이의 제조방법 및 약제로서 이의용도
KR950017970A (ko) 치환된 헤테로사이클릭 카복스아미드, 이의 제조방법 및 약제로서의 이의 용도
KR950032124A (ko) 설폰아미도카보닐피리딘-2-카복스아미드 및 이의 피리딘-n- 옥사이드, 이의 제조방법 및 약제로서의 이의 용도
KR950014072A (ko) 치환된 헤테로사이클릭 카복스아미드, 이의 제조방법 및 약제로서의 이의 용도
KR950032126A (ko) 설폰아미드카보닐 피리딘-2-카복스에스테르아미드 및 이의 피리딘-n- 옥사이드, 이의 제조방법, 및 약제로서의 이의 용도
JP2009540004A5 (ko)
US20210114987A1 (en) Enhanced erythropoiesis and iron metabolism
JP2009540000A5 (ko)
KR950032127A (ko) 치환된 헤테로사이클릭 카복스아미도에스테르, 이의 제조방법 및 약제로서의 이의 용도
US20070293575A1 (en) Compounds and methods for treatment of cancer-related anemia
ES418612A1 (es) Procedimiento para preparar derivados de 2-amino y 4-amino-quinazolina.
GB1496995A (en) 5-propoxy-3,4-dihydrocarbostyrils
KR900004710A (ko) 향정신성 작용을 갖는 피페라진디온
RU2018106474A (ru) Замещенные фурано-/тиеноциклоалкиламино-2-пиримидиновые производные и их применение для борьбы с нежелательным ростом растений
KR940009156A (ko) 아실설폰아미도피리딘-2-카복실산 에스테르와 설폰아미도 피리딘-2-카복실산 에스테르 및 이들의 피리딘 n-옥사이드, 이들의 제조 방법 및 약제로서의 이들의 용도
US20140309256A1 (en) Therapeutic Method
KR850000384A (ko) N-알킬화 아미노산 및 이의 에스테르의 제조방법
KR940005576A (ko) 4- 또는 5- (설프)이미도- 및 -(설폰)아미도피리딘과 이의 피리딘 n- 옥사이드, 이의 제조방법 및 약제로서의 이의 용도
KR880012542A (ko) 피롤리딘-2-(1,3-디카보닐)유도체, 이의 제조방법, 이를 함유하는 약제 및 이의 용도
KR950032125A (ko) 치환된 헤테로사이클릭 카복스아미드, 이의 제조방법 및 약제로서의 이의 용도
GB1212942A (en) 2-halo-1,1,1,3,3-pentafluoropropanes
GB1530675A (en) Guanidine derivatives
GB1369736A (en) Azaindene derivatives
IE38613B1 (en) Anti-microbial 2-aminoalkyl 3-phenyl-indoles and compositions containing them
GB1138207A (en) Process for the preparation of cyclododeca-1,5,9-triene

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application